EVERSANA, a global services provider to the life sciences sector, and Waltz Health, a digital health company centered around prescription care, are uniting to create a healthcare platform that brings a new perspective to the pharma commercialization and patient access market. By partnering up, Waltz Health’s software-powered drug-price marketplaces and direct-to-payer model will flow directly into EVERSANA’s commercialization services, providing a new angle on drug access and value.
Mark Thierer, co-founder and CEO of Waltz Health and chairman of EVERSANA, will serve as CEO of the newly-combined organization.
Merger aims to address cost and access challenges
The goal of this merger is to tackle misaligned industry incentives and fragmented patient experiences. The merger is expected to have a particularly strong impact on reducing costs for specialty medicines and high-expense drug classes such as GLP-1s.
Waltz’s tech platform, featuring an AI-powered prescription routing and affordability solution, is able to link the healthcare supply chains stakeholders: patients, health insurers, self-insured employers, governments, and pharmacy benefit managers (PBMs).
“This is a pivotal moment for the healthcare industry,” said Thierer. “By combining EVERSANA’s pharma services with Waltz’s technology-enabled payer solutions, we’re creating a unified platform that connects life sciences innovation directly to the organizations and individuals we’re meant to serve. This model is built to accelerate access, improve outcomes and deliver smarter, more transparent drug commercialization at every step.
“This combination brings together the scale and services of EVERSANA with Waltz Health’s payer-integrated platforms to create a company purpose-built for the future of life sciences. Together, we are launching a new-to-the-world model that directly connects manufacturers to patients and payers, delivering significant cost savings and improved patient outcomes to the healthcare system.”
Key areas of focus for the combined organization
Essentially, EVERSANA, considered a major player when it comes to providing a pharma and biotech commercialization and patient support, is growing its foundation via Waltz Health’s tech-enabled offerings that range from AI-driven pharmacy tools to payer marketplaces. This partnership provides access across a multitude of areas, including:
- Pharma commercialization: The combined organization brings together patient support services, field teams, digital outreach, reimbursement assistance, and real-world evidence, supported by modern software infrastructure.
- Payer connectivity: Waltz’s combination payer- and patient-facing tools are being incorporated into EVERSANA’s commercialization model, creating other channels for manufacturers to engage patients.
- Drug affordability and adherence: The merger brings net-price models, copay adjustments, and pharmacy routing into the fold, in order to help address patient abandonment and boost treatment continuity.
- Specialty pharmacy infrastructure: Waltz Connect’s tech-driven model is being combined with EVERSANA’s specialty pharmacy network to expand options for managing high-cost and limited-distribution therapies.
Merger follows mounting drug pricing pressure
The deal comes at a time when the pharma sector has to address issues pertaining to patient affordability, channel inefficiencies, and drug pricing. The latter is powered by actions conducted by President Trump in late July, when he issued letters to 17 of the largest pharmaceutical companies expressing urgency for making changes along the drug pricing front.2
These letters stem from an executive order (EO) he enacted on May 1 that essentially proclaimed that pharma companies need to treat the United States as a most-favored nation (MFN) as it pertains to drug pricing. The EO notes that US drug prices need to be less than or equal to the drug’s lowest price in other nations, as a way of establishing fairness.
A timeline for compliance has already been laid out, with compliance expected by Sept. 29.
References
1. EVERSANA Merges with Waltz Health to Create a New Force in Pharma Commercialization and Prescription Drug Access. PR Newswire. August 26, 2025. Accessed August 27, 2025. https://www.prnewswire.com/news-releases/eversana-merges-with-waltz-health-to-create-a-new-force-in-pharma-commercialization-and-prescription-drug-access-302538273.html
2. Saraceno N. Trump’s MFN Drug Pricing Push Targets 17 Big Pharma Companies, Spurs Global Industry Response. Pharmaceutical Commerce. August 1, 2025. Accessed August 27, 2025. https://www.pharmaceuticalcommerce.com/view/trump--mfn-drug-pricing-17-big-pharma-companies-spurs-global-industry-response
